Navigation Links
Gains made towards treatment of rare bone disease
Date:2/20/2013

This press release is available in French.

Diagnosed in toddlers, X-linked hypophosphatemia (XLH) is the most common form of heritable rickets, in which soft bones bend and deform, and tooth abscesses develop because infections penetrate soft teeth that are not properly calcified. Researchers at McGill University and the Federal University of Sao Paulo have identified that osteopontin, a major bone and tooth substrate protein, plays a role in XLH. Their discovery may pave the way to effectively treating this rare disease.

The findings were made by the laboratories of Marc McKee, a professor in the Faculty of Dentistry and the Department of Anatomy and Cell Biology at McGill University, and of Nilana M.T. Barros, a professor at the Federal University of Sao Paulo. The team built upon previous research that had shown that mutations in the single gene PHEX are responsible for causing XLH. The results of this latest research by Drs. McKee and Barros will be published in the March issue of the Journal of Bone and Mineral Research.

"XLH is caused in part by renal phosphate wasting, which is the urinary loss from the body of phosphate, an important building block of bones and teeth, along with calcium." says Prof. McKee. "In pursuing other factors that might contribute to XLH, we used a variety of research methods to show that PHEX enzymatic activity leads to an essentially complete degradation of osteopontin in bones."

This loss of osteopontin, a known potent inhibitor of mineralization (or calcification) in the skeleton and dentition, normally allows bones and teeth to mineralize and thus harden to meet the biomechanical demands placed on them. In XLH patients lacking functional PHEX enzyme, osteopontin and some of its smaller potent inhibitory peptides are retained and accumulate within the bone. This prevents their hardening and leads to soft deformed bones such as bowed legs (or knock-knees) seen in toddlers.

While not life-threatening, this decreased mineralization of the skeleton (osteomalacia), along with the soft teeth, soon leads to a waddling gait, short stature, bone and muscle pain, weakness and spontaneous tooth abscesses.

The fact that these symptoms are only partially improved by the standard treatment with phosphate which improves circulating phosphate levels prompted the researchers to look for local factors within the bone that might be blocking mineralization in these patients.

"With this new identification of osteopontin as a substrate protein for PHEX," says Professor Barros, "we can begin to develop an enzyme-replacement therapy to treat XLH patients who have nonfunctional PHEX, much as has been done using a different enzyme to treat another rare bone disease called hypophosphatasia."


'/>"/>

Contact: Cynthia Lee
cynthia.lee@mcgill.ca
514-398-6754
McGill University
Source:Eurekalert

Related medicine news :

1. Scientists identify major source of cells defense against oxidative stress
2. Omega-3 Supplements No Help Against Repeat Heart Trouble: Review
3. Kinase test may yield big gains for drug-resistant cancers
4. Will women use microbicides to protect themselves against HIV?
5. Vitamin E in diet protects against many cancers
6. Lower-Dose Radioiodine Effective Against Thyroid Cancer
7. Study identifies possible protective blood factors against Type 2 diabetes
8. New study of NIH funding allocations suggests potential efficiency gains
9. Stem Cell Study Shows Promising Results Against Heart Failure
10. Blood pressure drugs dont protect against colorectal cancer
11. CNIO scientists successfully test the first gene therapy against aging-associated decline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... expansion and facility enhancement of their 503A compounding pharmacy located in Ocala, Florida. ... demand of physicians and patients throughout the United States for high-quality human ...
(Date:1/19/2017)... ... January 19, 2017 , ... Remote ... recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound System. ... to RMT technology that delivers HD, dynamic, streaming ultrasound images and video to ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, ... were used to facilitate a recapitalization of MedPro led by Harren Equity Partners. ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Tranquility acoustic and privacy panel system. , The Tranquility privacy panel system ... a collaborative office environment. Tranquility panels help reduce noise and provide the visual ...
(Date:1/19/2017)... ... ... Tribble Insurance Agency, a family owned and operated firm offering asset protection ... to honor Chad Phillip Dermyer, a local police trooper who was shot and killed ... fellow officers were conducting routine stops of suspects when one of them, a violent ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , January 19, 2017 According to a ... cryotherapy is set to witness a CAGR of 6.5% during the ... will continue to be the leading market for cryotherapy ... ... are emphasizing on ensuring affordable and adequate supply of gas in ...
(Date:1/19/2017)... , January 19, 2017 ... ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... Published recently in a ... peer-reviewed journal from touchONCOLOGY, an article by ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
Breaking Medicine Technology: